Pharma MSMEs seek government intervention to tackle shortage, price increase of raw materials
Caution that if the situation continues, there could be a scarcity of medicines in the country
The pharma MSME segment informs that COVID-19 has impacted it adversely and they are facing the brunt in the form of a decrease in demand, shortage of working capital, non-availability of finance/funding by financial institutions, shortage of input materials, exorbitant increase in raw material cost, cancellation of export orders, logistic problems, non-availability of manpower etc. So, the MSME segment of the pharma industry is seeking the government authorities’ intervention to deal with the challenges.
B R Sikri, Chairman, FOPE, highlighted, “The factors that have compounded the issue are the un